Publications by authors named "D Papakosta"
Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. In this post hoc analysis of the RELIght study, we aimed to evaluate clinical remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. Clinical remission was defined as the absence of asthma exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function.
View Article and Find Full Text PDFPrevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients.
Sarcoidosis Vasc Diffuse Lung Dis
December 2024
Background And Aim: There is limited data on the prevalence of SARS-COV-2 in sarcoidosis patients and the underlying parameters linked to severity. We aimed to conduct a national multicenter study to explore the prevalence of SARS-COV-2 in sarcoidosis patients and investigate its impact on hospitalization and infection rates, describe the characteristics of the infected population and assess the role of these characteristics in determining the likelihood of infection or hospitalization.
Methods: We recruited all the adult sarcoidosis patients with who were examined across eight Greek Health Interstitial Lung Disease Referral Centers from the beginning of the pandemic until August 1, 2022.
Article Synopsis
- The STEPINCOPD study investigated the factors influencing the escalation or de-escalation of inhaled COPD therapies in clinical practice, especially after updated guidelines were released in 2019 and 2020.
- Conducted over 12 weeks with 1429 patients from various centers in Greece, the study focused on understanding why patients had changes in their inhaled medication based on GOLD's 2021 recommendations.
- Findings revealed that reasons for treatment changes included lack of response to previous treatment and COPD exacerbations, with a high adherence rate (over 80%) to the GOLD recommendations among physicians, influenced by factors such as their age and patients' CAT scores.
Background: Clinical trials and real-world experience have provided evidence for the clinical benefits of mepolizumab, an anti-IL-5 biologic, in severe asthma. However, limited data exist regarding the impact of mepolizumab on airway remodeling.
Objective: We sought to investigate the effect of mepolizumab on airway structural remodeling in patients treated for severe asthma in routine clinical care.
Background: Electronic cigarettes (ECs) have been promoted as alternatives to traditional cigarettes.
Aim: To investigate ECs' effects on respiratory system, especially in patients with respiratory diseases.
Methods: We randomly selected 25 smokers with stable moderate asthma and matched them with 25 healthy smokers.